• Grifols will shift to a two-system operating model, aligning U.S.-sourced plasma with U.S. demand, ROW plasma with Europe and other markets.
• Operating platforms will move toward greater autonomy, with separate functions, upgraded controls, stronger compliance, and expanded financial reporting.
• Dedicated Biopharma U.S. and Biopharma ROW commercial organizations will lead execution, with Felipe Palacios running U.S. operations, Thierry Heinrich leading ROW.
• Plan targets lower reliance on higher-cost U.S. plasma for lower-priced international markets, aiming to lift resilience, profitability, and margins over time.
• Grifols Egypt for Plasma Derivates will invest an additional EUR 180 million, targeting 1,000,000 liters collected in 2026, ramping to 3,000,000 liters by 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grifols SA published the original content used to generate this news brief on July 01, 2026, and is solely responsible for the information contained therein.